Drug General Information
Drug ID	D08EYQ
Former ID	DIB011613
Drug Name	ORE-1001
Synonyms	GL-1001; ACE2 enzyme inhibitor (inflammatory bowel disease), Ore Pharmaceuticals
Indication	Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1]		Phase 1/2	[522906]
Company	Millennium Pharmaceuticals Inc
Structure		Download 2D MOL 3D MOL
Canonical SMILES	n1(c(C[C@H](N[C@@H](CC(C)C)C(=O)O)C(=O)O)cnc1)Cc1cc(cc(<br />c1)Cl)Cl
CAS Number	CAS 305335-31-3
Target and Pathway
Target(s)	Recombinant human angiotensin converting enzyme 2	Target Info	Inhibitor	[530201]
KEGG Pathway	Renin-angiotensin system
	Protein digestion and absorption
Reactome	Metabolism of Angiotensinogen to Angiotensins
WikiPathways	ACE Inhibitor Pathway
	Metabolism of Angiotensinogen to Angiotensins
References
Ref 522906	ClinicalTrials.gov (NCT01039597) Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis. U.S. National Institutes of Health.
Ref 530201	Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res. 2009 Nov;58(11):819-27.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.